Navigation Links
ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
Date:4/30/2008

her, the higher concentration of Bepreve demonstrated a once-daily clinical effect that was comparable to the published literature for FDA-approved once-daily ophthalmic solutions studied in patients with ocular allergies.

The data announced today mirror the results from the 107-patient, single- center Phase III Bepreve study, announced May 8, 2007, which used the same study design. ISTA currently is analyzing the results of an ocular safety study in approximately 850 patients, with preliminary results anticipated before the end of the second quarter of 2008. Once the Company completes its analysis of the full dataset, ISTA expects to file a New Drug Application (NDA) with the FDA during the second half of 2008. ISTA plans to discuss the study results with the FDA to determine what, if any, additional information would be required in order to obtain approval for both a once-daily and twice- daily form of Bepreve.

About Bepreve(TM) (bepotastine ophthalmic solution)

Bepreve has three primary mechanisms of action: it is a non-sedating, highly selective antagonist of the histamine 1 (H1) receptor, it has a stabilizing effect on mast cells, and it suppresses the migration of eosinophils into inflamed tissues. The compound's primary mechanisms of action are believed to make it an effective treatment against the signs and symptoms of allergic conjunctivitis.

Bepotastine was approved in Japan for use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by Mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the brand name TALION(R). TALION was co-developed by Tanabe Seiyaku and Ube Industries, Ltd., who discovered bepotastine. In 2001, Tanabe Seiyaku granted Senju Pharmaceutical Co., Ltd., exclusive worldwide rights, with the exception of certain Asian countries, to develop, manufacture, and market bepotastine for ophthalmic use. In 2
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
2. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
3. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
4. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
5. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
6. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
7. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
8. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
9. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)...  Decision Resources Group finds that the laparoscopic device ... will increase to a value of over $4.3 billion ... in the large direct energy device market. In particular, ... due to the advantages they offer and as new ... Decision Resources Group,s coverage of the U.S. laparoscopic device ...
(Date:12/19/2014)... KANSAS CITY, Kan. , Dec. 18, 2014 ... PETX ), a biopharmaceutical company focused on ... for companion animals, today announced positive results from ... company,s innovative drug for treating pain in dogs ... demonstrated improvements in pain assessment scores that were ...
(Date:12/17/2014)... 17, 2014 Revenue and earnings above ... research and development In the past 2013/14 fiscal ... two percent to EUR 4.287 billion (last year: EUR 4.190 ... percent to EUR 360 million. "Overall, 2013/14 was a successful ... Kaschke , President and CEO of Carl Zeiss AG. "Thanks ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2
... SAN DIEGO , April 27 ResMed Inc. (NYSE: RMD ) ... , , ... Boston on May 4, 2010 ; Jefferies Global Life Sciences Conference ... ; William Blair Growth Stock Conference at the Four Seasons in Chicago ...
... 27 Volcano Corporation (Nasdaq: VOLC ), ... guidance tools designed to enhance the diagnosis and treatment ... it has entered into a distribution agreement with AngioScore ... indications in Japan . This is the first ...
Cached Medicine Technology:ResMed Inc. to Present at Upcoming Conferences 2Volcano Announces Distribution Agreement With AngioScore for the AngioSculpt(R) PTCA Scoring Balloon Catheter in Japan 2Volcano Announces Distribution Agreement With AngioScore for the AngioSculpt(R) PTCA Scoring Balloon Catheter in Japan 3Volcano Announces Distribution Agreement With AngioScore for the AngioSculpt(R) PTCA Scoring Balloon Catheter in Japan 4
(Date:12/19/2014)... Colorado (PRWEB) December 20, 2014 It’s very ... travel is something that is put to the wayside until ... who still have that travel “itch” and that burning desire ... Montrose accommodates families on their journey to Telluride with a ... get visitors to and from the resort, and ensure that ...
(Date:12/19/2014)... 19, 2014 The Plantrician ... developing educational events, tools and resources for healthcare ... School , the world’s leading online cooking school, ... human being needs: Culinary Rx. As an online ... Culinary Rx, scheduled for debut spring 2015, will ...
(Date:12/19/2014)... These vanadium reserves are mostly found in China, ... of vanadium were produced globally in 2013, up 11% ... 6.7% AAGR during the period from 2001 to 2013, ... largest consumer, accounted for more than 90% of total ... the chemical industry. , View Full Report at ...
(Date:12/19/2014)... research warns parents that buying an older car for their teens ... teen drivers killed in the United States between 2008 and 2012 ... often lacked important safety features that are available on newer cars, ... crashes were in cars at least six years old, 34 percent ... in cars 11 to 15 years old, and 17 percent were ...
(Date:12/19/2014)... drug users who also use cocaine and amphetamines have ... users, a new study finds. "We know that ... attempt and completed suicide," Didier Jutras-Aswad, a psychiatry professor ... news release. "However, there are many different profiles of ... users were actually more likely to attempt suicide." ...
Breaking Medicine News(10 mins):Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3Health News:Older Cars a Bad Choice for Younger Drivers 2Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2
... , FRIDAY, Sept. 16 (HealthDay News) -- People ... clotting and inflammation have a lower five-year survival rate ... findings should be used to better treat and ensure ... said the research team from Duke University Medical Center ...
... GALVESTON, September 16, 2011 Researchers have shown for the ... cells by binding to and rendering inert protein p53, a ... of Texas Medical Branch may lead to treatments for a ... and appears in the current print issue of the ...
... has awarded $11.3 million to Case Western Reserve University ... for research on gastrointestinal cancers. The funding designates the ... in Gastrointestinal (GI) Cancers recognition extended to just ... is the primary affiliate of Case Western Reserve and ...
... WINSTON-SALEM, N.C. Sept. 16, 2011 A study ... colleagues suggests that a high intake of calcium causes ... absorbers of the mineral. "High dietary intake of ... the explanation for this observation has been elusive," said ...
... (USC) epidemiologists suggests that a high intake of calcium ... good absorbers of the mineral. "High dietary intake ... and this study suggests that these associations are likely ... professor of preventive medicine at the Keck School of ...
... highlight Pain Awareness Month in September, The ... interdisciplinary organization devoted to the field of aging is ... for seniors. Paired with its other recent research findings, ... advances in pain prevention, treatment, and management may improve care ...
Cached Medicine News:Health News:Gene Variant May Raise Death Risk After Heart Bypass 2Health News:Researchers identify potential molecular target to prevent growth of cancer cells 2Health News:National Cancer Institute establishes $11.3 million center at Case Western Reserve 2Health News:National Cancer Institute establishes $11.3 million center at Case Western Reserve 3Health News:National Cancer Institute establishes $11.3 million center at Case Western Reserve 4Health News:National Cancer Institute establishes $11.3 million center at Case Western Reserve 5Health News:National Cancer Institute establishes $11.3 million center at Case Western Reserve 6Health News:Genetics may explain why calcium increases risk for prostate cancer 2Health News:Genetics may predict why calcium increases risk for prostate cancer 2Health News:GSA sets focus on optimizing older adults' pain care 2
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
... KWIK-QC Slides have a positive and ... sample inoculation. With these slides, perform QC ... ,Laboratories enhance their education and training programs ... and interpretation, all on one slide! KWIK-QC ...
Each slide contains Giardia lamblia trophozoites applied as a mono-layer to the side....
Each slide contains a high yield of concentrated C. parvum oocysts within the positive control well. A negative control well is also included....
Medicine Products: